Logo image of VIR

VIR BIOTECHNOLOGY INC (VIR) Stock Fundamental Analysis

NASDAQ:VIR - US92764N1028 - Common Stock

4.94 USD
-0.1 (-1.98%)
Last: 8/29/2025, 8:00:02 PM
5 USD
+0.06 (+1.21%)
After Hours: 8/29/2025, 8:00:02 PM
Fundamental Rating

3

Overall VIR gets a fundamental rating of 3 out of 10. We evaluated VIR against 547 industry peers in the Biotechnology industry. VIR has a great financial health rating, but its profitability evaluates not so good. VIR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

VIR had negative earnings in the past year.
VIR had a negative operating cash flow in the past year.
In multiple years VIR reported negative net income over the last 5 years.
In the past 5 years VIR reported 4 times negative operating cash flow.
VIR Yearly Net Income VS EBIT VS OCF VS FCFVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

1.2 Ratios

VIR's Return On Assets of -46.14% is in line compared to the rest of the industry. VIR outperforms 53.02% of its industry peers.
With a decent Return On Equity value of -58.07%, VIR is doing good in the industry, outperforming 61.97% of the companies in the same industry.
Industry RankSector Rank
ROA -46.14%
ROE -58.07%
ROIC N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
VIR Yearly ROA, ROE, ROICVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

With an excellent Gross Margin value of 96.08%, VIR belongs to the best of the industry, outperforming 94.88% of the companies in the same industry.
VIR's Gross Margin has improved in the last couple of years.
VIR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
VIR Yearly Profit, Operating, Gross MarginsVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

More info and screens

7

2. Health

2.1 Basic Checks

VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VIR has more shares outstanding
Compared to 5 years ago, VIR has more shares outstanding
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VIR Yearly Shares OutstandingVIR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VIR Yearly Total Debt VS Total AssetsVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

VIR has an Altman-Z score of -0.45. This is a bad value and indicates that VIR is not financially healthy and even has some risk of bankruptcy.
VIR's Altman-Z score of -0.45 is fine compared to the rest of the industry. VIR outperforms 60.33% of its industry peers.
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.45
ROIC/WACCN/A
WACC9.69%
VIR Yearly LT Debt VS Equity VS FCFVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

VIR has a Current Ratio of 7.01. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VIR (7.01) is better than 68.56% of its industry peers.
A Quick Ratio of 7.01 indicates that VIR has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.01, VIR is doing good in the industry, outperforming 68.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.01
Quick Ratio 7.01
VIR Yearly Current Assets VS Current LiabilitesVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for VIR have decreased strongly by -11.73% in the last year.
Looking at the last year, VIR shows a very negative growth in Revenue. The Revenue has decreased by -75.90% in the last year.
Measured over the past years, VIR shows a very strong growth in Revenue. The Revenue has been growing by 55.74% on average per year.
EPS 1Y (TTM)-11.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.57%
Revenue 1Y (TTM)-75.9%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-60.52%

3.2 Future

VIR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.23% yearly.
VIR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.19% yearly.
EPS Next Y12.81%
EPS Next 2Y10.76%
EPS Next 3Y9.79%
EPS Next 5Y10.23%
Revenue Next Year-82.71%
Revenue Next 2Y-56.46%
Revenue Next 3Y-33.91%
Revenue Next 5Y7.19%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VIR Yearly Revenue VS EstimatesVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
VIR Yearly EPS VS EstimatesVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VIR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIR Price Earnings VS Forward Price EarningsVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIR Per share dataVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.76%
EPS Next 3Y9.79%

More info and screens

0

5. Dividend

5.1 Amount

VIR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIR BIOTECHNOLOGY INC

NASDAQ:VIR (8/29/2025, 8:00:02 PM)

After market: 5 +0.06 (+1.21%)

4.94

-0.1 (-1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-24 2025-07-24/bmo
Earnings (Next)10-29 2025-10-29/amc
Inst Owners66.05%
Inst Owner Change18.57%
Ins Owners1.16%
Ins Owner Change-0.55%
Market Cap686.26M
Analysts80
Price Target17.98 (263.97%)
Short Float %10.64%
Short Ratio9.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.87%
Min EPS beat(2)-9.48%
Max EPS beat(2)-4.26%
EPS beat(4)1
Avg EPS beat(4)-11.67%
Min EPS beat(4)-46.72%
Max EPS beat(4)13.76%
EPS beat(8)3
Avg EPS beat(8)1.33%
EPS beat(12)4
Avg EPS beat(12)48.76%
EPS beat(16)7
Avg EPS beat(16)213.56%
Revenue beat(2)0
Avg Revenue beat(2)-60.45%
Min Revenue beat(2)-65.06%
Max Revenue beat(2)-55.84%
Revenue beat(4)1
Avg Revenue beat(4)-31.9%
Min Revenue beat(4)-65.06%
Max Revenue beat(4)50.52%
Revenue beat(8)3
Avg Revenue beat(8)18.98%
Revenue beat(12)5
Avg Revenue beat(12)13.12%
Revenue beat(16)7
Avg Revenue beat(16)5.49%
PT rev (1m)0%
PT rev (3m)-47.5%
EPS NQ rev (1m)-19.71%
EPS NQ rev (3m)1.58%
EPS NY rev (1m)-6.57%
EPS NY rev (3m)1.87%
Revenue NQ rev (1m)-20.55%
Revenue NQ rev (3m)-80.27%
Revenue NY rev (1m)-32.34%
Revenue NY rev (3m)-31.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36.12
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-4
EYN/A
EPS(NY)-2.95
Fwd EYN/A
FCF(TTM)-3.36
FCFYN/A
OCF(TTM)-3.29
OCFYN/A
SpS0.14
BVpS6.82
TBVpS6.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.14%
ROE -58.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.08%
FCFM N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.21%
Cap/Sales 47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.01
Quick Ratio 7.01
Altman-Z -0.45
F-Score2
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)387.02%
Cap/Depr(5y)331.46%
Cap/Sales(3y)13.03%
Cap/Sales(5y)9.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.57%
EPS Next Y12.81%
EPS Next 2Y10.76%
EPS Next 3Y9.79%
EPS Next 5Y10.23%
Revenue 1Y (TTM)-75.9%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-60.52%
Revenue Next Year-82.71%
Revenue Next 2Y-56.46%
Revenue Next 3Y-33.91%
Revenue Next 5Y7.19%
EBIT growth 1Y-11.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.81%
EBIT Next 3Y6.4%
EBIT Next 5Y7.12%
FCF growth 1Y-13.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.4%
OCF growth 3YN/A
OCF growth 5YN/A